Day: January 9, 2023

Refreshed logo and branding exemplifies the success and mission of Health-ISAC

Health-ISAC logo

Health-ISAC logo

ORMOND BEACH, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) — Health-ISAC, a nonprofit, member driven organization, has unveiled a new logo and branding scheme to reflect its commitment to ensuring the strength and perseverance of the health sector in the face of both cyber and physical threats.

The new logo demonstrates the key role Health-ISAC has in the global security community, which includes the collaboration between 8,000 security professionals in its global network, key stakeholders in the healthcare ecosystem, and external partners.

The logo features three key brand elements:

• A globe crisscrossed with connected grid lines, representing the value of connecting diverse healthcare organizations and security professionals worldwide and empowering trusted relationships. The ability to share real-time intelligence and best practices helps members protect their organizations, the healthcare ecosystem and, ultimately, patients.
• An EKG line representing Health-ISAC’s focus on improving health and saving lives by anticipating, analyzing and overcoming cyber and physical security threats. Health-ISAC is the pulse of the sharing community.
• The tagline “Collaborating for Resilience in Healthcare,” expressing Health-ISAC’s mission to strengthen operational resilience by sharing timely, actionable, and relevant information in a trusted, collaborative environment.

“Our newly refreshed brand dynamically highlights that through connection, we are better and stronger together,” said Denise Anderson, President and CEO, Health-ISAC. “We look forward to continuing to strengthen the ability of our members to ensure their organizations, the health sector and ultimately, patients, remain resilient against the multiple threats they face every single day.”

ABOUT HEALTH-ISAC

Health-ISAC — a non-profit, private sector, member-driven organization — plays an essential role in providing situational awareness around cyber and physical security threats to the Healthcare Sector so that companies can detect, mitigate, and respond to ensure operational resilience. Health-ISAC connects thousands of healthcare security professionals worldwide to share peer insights, real-time alerts, and best practices in a trusted, collaborative environment. As the go-to source for timely, actionable, and relevant information, Health-ISAC is a force-multiplier that enables healthcare organizations of all sizes to enhance situation awareness, develop effective mitigation strategies and proactively defend against threats every single day.

Contact Information:
Julia Annaloro
Marketing and Communications Associate
jannaloro@h-isac.org
+1-321-593-1470

Related Images

Image 1: Health-ISAC logo

Collaborating for Resilience in Healthcare

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Health-ISAC logo

GlobeNewswire Distribution ID 8725692

New era for green tech alternatives to replace petrochemical synthesized dyes.

Bedford, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Conagen announced the successful scale-up of its sustainable, cost-effective Tyrian purple, a historically coveted and expensive dye found in rare and limited sources in marine nature.

Conagen is the world’s first and only biotechnology company commercializing a sustainable Tyrian purple by fermentation. As with any biologically-sourced textile dye, this color-fast compound reduces pollution and carbon footprints when used as an alternative to petrochemically synthesized dyes commonly used in the textiles industry today.

Also known as Phoenician purple, royal purple, imperial purple, or imperial dye, this rare dye dates back several millennia to the bronze age when the Phoenicians from Tyre, Lebanon, on the Levantine coast, produced it for the ancient Greeks, Persians, Byzantines, and the Roman empire to clad emperors and kings with luxury textiles. Tyrian purple was once worth more than its weight in gold for its prized deep rich purple. In 301 CE, during the Roman Empire, one pound of Tyrian purple dye was priced at approximately three Troy pounds of gold, roughly $66,000 in today’s currency.

Current producers extract and harvest Tyrian purple from the murex shellfish in much the same way as the ancient Phoenicians. Thousands — approximately 10,000 or (54 kilograms (119 lb.) of these predatory sea snails are required to make diminishing quantities of Tyrian purple to produce 1 gram of the dye, making it impracticable, expensive, and environmentally unfriendly. Ancient dye producers all but drove the murex species to extinction along the coasts of Phoenicia, evident in the vast deposits of the shells excavated on the outskirts of Sidon, Tyre, and across the Mediterranean.

Conagen’s Tyrian purple, produced by precision fermentation and bioconversion, is a natural, sustainable dye ideal for textile companies under pressure to deliver fashions more sustainably and with a reduced global environmental footprint, especially from manufacturing.

“Conagen is democratizing the exclusive use of a color once reserved for royalty — now obtainable on a global scale,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “Our fermentation and bioconversion technologies enable us to offer true-to-nature products. By leveraging Conagen’s bioengineering and commercial manufacturing capabilities, we’re unlocking Tyrian purple’s great potential as an accessible and sustainable dye. We expect Tyrian purple to inspire fresh ideas in multiple industries, making this rare and exciting color more marketable with planet-conscious consumers.”

The Tyrian purple technology is based on two of Conagen’s many key bioengineering platforms, which enable accelerated product development timelines for its competitive phenolics, terpenoids, proteins, and peptide molecules.

As an example, Conagen’s phenolics platform was used to make an important antioxidant, hydroxytyrosol, the active health ingredient found in oil, juice, and fruit in olives. Using another platform, Conagen has optimized the production of different amino acid-based products, including the nutraceutical antioxidant ergothioneine, a “longevity vitamin” currently branded as “Ergoactive” by Conagen’s pipeline partner Blue California. To produce the Tyrian purple, Conagen drew from both proprietary platforms to develop novel enzymes which increase the conversion efficiency of precursors to the dye.

“Conagen has further solidified its leadership in the bioeconomy by rapidly producing multiple novel and interesting molecules, such as Tyrian purple,” said Lippmeier. “Our technology platforms have been meticulously engineered and improved upon for over a decade, and they are extremely efficient at making targeted compounds from an expanding array of molecular classes for our internal product development and collaborative ventures.”

Conagen aims to replace petroleum-based ingredients and reduce carbon footprints with green technologies. Tyrian purple adds to Conagen’s natural color offerings, including several carotenoids made by fermentation which have been scaled to global production. As a dye, Tyrian purple is ideal for textile fabrics, clothing, handbags, and related accessories.

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use modern synthetic biology tools to program micro-organisms and enzymes on a molecular level to produce high-quality, sustainable, natural products manufactured worldwide via precision fermentation and bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceuticals, and renewable materials.

Attachments

• Bolinus brandaris, also called sea snail or purple dye murex
• Tyrian purple dye for textiles

Ana Arakelian, Head of Public Relations and Communications
Conagen
+1-781-271-1588
ana.arakelian@conagen.com

GlobeNewswire Distribution ID 8725973

Grid connection and power quality solution for the MFW Baltyk II and MFW Baltyk III offshore wind farms will help Poland progress towards its renewable energy goal and provide emission-free electricity for more than 2 million Polish homes.

Zurich, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) — Zurich, Switzerland, January 9, 2023 – Hitachi Energy, a global technology leader that is advancing a sustainable energy future for all, today announced it has won two major orders from Equinor and Polenergia to provide an AC grid connection and power quality solution for their jointly owned MFW Baltyk II and MFW Baltyk III offshore wind farms, with a combined generating capacity of 1,440 megawatts in the Polish sector of the Baltic Sea.

Hitachi Energy will provide each of the two wind farms with an offshore grid connection that will receive the power from the wind turbines and transfer it to shore, a mainland grid connection that will transmit the power into the national transmission system, and a STATCOM power quality solution to ensure that power flows reliably and stably at optimal capacity and at all times, despite the often high variability of wind power.

MFW Baltyk II and MFW Baltyk III are pending a final investment decision in 2024, and are scheduled to deliver first power in 2027. They will be one of the first offshore wind farms in Poland and part of the country’s ambitious program to develop its offshore wind potential and increase the use of renewables in its electricity mix, which historically is dominated by coal. The government aims to have around 11 gigawatts of offshore wind capacity either operational or under development by 2027¹.

Hitachi Energy was selected in a competitive procurement process on the strength of its front-end engineering and design (FEED) studies and optimized solutions, its long track record of project execution excellence, and its close working relationships over many decades with Equinor and PSE (Poland’s transmission system operator) and, most recently, Polenergia.

“Integrating large-scale renewable energy sources with the power grid is a key enabler of the energy transition and a field in which we have been a pioneer for decades,” said Niklas Persson, Managing Director of Hitachi Energy’s Grid Integration business. “Our grid connection technologies feature in offshore wind farms worldwide, and our power quality solutions resolve bottlenecks and keep the voltage stable and the energy flowing in power systems globally.”

These project awards further underscore Hitachi Energy’s position as a global leader in the offshore wind market and the partner of choice for wind farm developers, combining solid experience with grid technologies to help make the world’s energy system more sustainable, flexible and secure by enabling new solutions and business models to be deployed at scale and with speed.

The company has been continuously developing its portfolio to better serve this market with the recent launch of its Grid-eXpand range of modular and prefabricated grid connection solutions that make it faster, simpler and more efficient to connect offshore wind farms to mainland grids, and with its complete portfolio of STATCOMs and E-STATCOMs for all power ranges, ensuring grid stability and power quality at all times.

The announcement follows a recent global agreement between Hitachi Energy and Equinor to collaborate on high-voltage transmission systems (AC and DC) to connect Equinor offshore wind farms and production facilities to mainland power grids worldwide.

1Global Wind Energy Council – Global Offshore Wind Report 2022

About Hitachi Energy Ltd.

Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 40,000 people in 90 countries and generate business volumes of approximately $10 billion USD.

https://www.hitachienergy.com

https://www.linkedin.com/company/hitachienergy

https://twitter.com/HitachiEnergy

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachment

• Hitachi Energy awarded major orders to integrate two large offshore wind farms with Poland’s power grid

Jocelyn Chang
Hitachi Energy
+41793847775
jocelyn.chang@hitachienergy.com

GlobeNewswire Distribution ID 8725982

TEMECULA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy and Industrial Gases Group (“Group”), a part of Nikkiso Co., Ltd (Japan), has entered into an agreement to acquire Cryotec Anlagenbau GmbH, (Wurzen close to Leipzig, Saxony, Germany) for an undisclosed amount.

A global plant engineering and construction company, Cryotec provides planning, project management, manufacturing and engineering services of skid-mounted/containerized air separation and liquefaction plants, and CO2 technologies offering tailored solutions to their customers.

Cryotec will operate as part of the Group’s GmbH facility, based in Neuenburg am Rhine, Germany. The Group consists of six functional business units: Cryogenic Pumps, Heat Exchanger Systems, Process Systems, Fueling & Solutions, Energy Infrastructure & Strategic Projects and Service.

“Our acquisition of Cryotec will allow the Group to expand our footprint in Europe, and broaden our expertise in carbon capture and biogas technologies”, according to Ole Jensen, Vice President, Europe.

“We look forward to bringing Cryotec into our Nikkiso family. This acquisition exemplifies our passion to provide, efficient, performance-based products and service,” according to Peter Wagner, CEO of Cryogenic Industries and President of the Group.

This acquisition represents their commitment to and support of the European market. The acquisition is expected to close during Q1, 2023

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture, and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.NikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

GlobeNewswire Distribution ID 8725755

เตเมคูลา,แคลิฟอร์เนีย, Jan. 09, 2023 (GLOBE NEWSWIRE) — กลุ่มพลังงานสะอาดและก๊าซอุตสาหกรรมของกลุ่ม Nikkiso Cryogenic Industries (“กลุ่มบริษัท”) ซึ่งอยู่ในเครือของ Nikkiso Co., Ltd (ประเทศญี่ปุ่น) ได้ทำข้อตกลงเพื่อเข้าซื้อกิจการ Cryotec Anlagenbau GmbH (Wurzen ใกล้กับ Leipzig, Saxony, เยอรมนี) ด้วยจำนวนเงินที่ไม่เปิดเผย

Cryotec เป็นบริษัทด้านวิศวกรรมและการก่อสร้างโรงงานระดับโลก ให้บริการด้านการวางแผน การจัดการโครงการ การผลิตและวิศวกรรมของโรงงานแยกอากาศและของเหลวแบบติดตั้งบนระบบไหลเวียน/ตู้คอนเทนเนอร์ และเทคโนโลยี CO2 ที่นำเสนอโซลูชันที่ปรับให้เหมาะสมกับลูกค้า

Cryotec จะดำเนินการโดยเป็นส่วนหนึ่งของโรงงาน GmbH ของกลุ่มบริษัท ซึ่งตั้งอยู่ใน Neuenburg am Rhine เยอรมนี ในกลุ่มบริษัทประกอบไปด้วยหกหน่วยธุรกิจได้แก่: ปั๊มไครโอเจนิก ระบบแลกเปลี่ยนความร้อน ระบบกระบวนการ เชื้อเพลิงและโซลูชัน โครงสร้างพื้นฐานด้านพลังงานและโครงการเชิงกลยุทธ์และการบริการ

“การซื้อกิจการ Cryotec ของเราจะช่วยให้กลุ่มบริษัทสามารถขยายขอบเขตการดำเนินงานของเราในยุโรป และขยายความเชี่ยวชาญเทคโนโลยีของเราในการดักจับคาร์บอนและก๊าซชีวภาพ” Ole Jensen รองประธานประจำยุโรปกล่าว

“เราเฝ้ารอที่จะพา Cryotec เข้ามาสู่ครอบครัว Nikkiso ของเรา การซื้อกิจการครั้งนี้แสดงให้เห็นถึงความทุ่มเทของเราในการจัดหาผลิตภัณฑ์และบริการตามประสิทธิภาพได้อย่างมีประสิทธิภาพ” Peter Wagner ประธานเจ้าหน้าที่บริหารของ Cryogenic Industries และประธานกลุ่มบริษัทกล่าว

การซื้อกิจการครั้งนี้แสดงให้เห็นถึงความมุ่งมั่นและการให้การสนับสนุนต่อตลาดยุโรปของพวกเขา การเข้าซื้อกิจการคาดว่าจะเสร็จสิ้นในช่วง Q1 ปี 2566

เกี่ยวกับCRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (ปัจจุบันเป็นสมาชิกของ Nikkiso Co., Ltd.) บริษัทในเครือผลิตและให้บริการอุปกรณ์แปรรูปก๊าซไครโอเจนิกเชิงวิศวกรรม (ปั๊ม เครื่องขยายเทอร์โบ เครื่องแลกเปลี่ยนความร้อน ฯลฯ) และโรงงานแปรรูปก๊าซอุตสาหกรรม ก๊าซธรรมชาติเหลว (LNG) ไฮโดรเจนเหลว (LH2) และวัฏจักรแรนไคน์อินทรีย์สำหรับการกู้คืนความร้อนเหลือทิ้ง Cryogenic Industries ก่อตั้งขึ้นเมื่อกว่า 50 ปีที่แล้ว เป็นบริษัทแม่ของ ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne และ Cryoquip และกลุ่มที่ควบคุมร่วมกันซึ่งมีหน่วยงานดำเนินงานประมาณ 20 แห่ง

สำหรับข้อมูลเพิ่มเติมโปรดติดต่อที่ www.NikkisoCEIG.com และ www.nikkiso.com

ติดต่อฝ่ายสื่อ:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

GlobeNewswire Distribution ID 8725757

PRESS RELEASE

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications

Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, today announced that it has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs).

Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and tolerability profile. Following highly promising results from a Phase 2 study conducted with mavoglurant in cocaine-use disorder (CUD; NCT03242928), STALICLA is now preparing to advance mavoglurant into Phase 3 development for the treatment of CUD.

In parallel, STALICLA will leverage its precision neurobiology drug development platform (DEPI), which has demonstrated proof-of-concept in other neurodevelopmental programs, to detect subgroups of high responder patients with rare and common neurodevelopmental disorders where mavoglurant can be an effective treatment, as guided by earlier clinical studies.

The market potential of the CUD and NDD indications alone could top €2 billion globally.

Lynn Durham, STALICLA’s CEO & Founder, commented: “This agreement with Novartis is a testament to the strength of our precision neurobiology medicine platform and we are excited about this transaction to further develop mavoglurant and to bring it to the right patients. STALICLA stratifies patient subgroups and identifies compounds that may provide medical benefit in neurodevelopmental indications with clear unmet need. Our unique model benefits all healthcare stakeholders and is a key driver of the Company’s rapid growth. With two Phase 2 and a Phase 3 trial slated to start within a year, alongside strong IP, we are well positioned to continue our exciting growth trajectory.”

Under the terms of the agreement, STALICLA has acquired worldwide rights to mavoglurant for substance-use disorders, neurodevelopmental disorders, and other indications in exchange for upfront fees and equity, and development and commercial milestones of up $270m, plus royalties on sales.

About Mavoglurant

Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist. mGluR5 has been tied to mood disorders, addiction as well as rare and common forms of Autism. In clinical Phase 2 studies, mavoglurant induces abstinence in CUD patients through inhibition of mGluR5, with no evidence of withdrawal liability.

About STALICLA

STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.

STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.

With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.

The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.

STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform towards revenue generation.

For further information, please visit: https://stalicla.com/

Contacts

GlobeNewswire Distribution ID 1000776062